CN114127274A - 新型omni-50 crispr核酸酶 - Google Patents

新型omni-50 crispr核酸酶 Download PDF

Info

Publication number
CN114127274A
CN114127274A CN202080032631.5A CN202080032631A CN114127274A CN 114127274 A CN114127274 A CN 114127274A CN 202080032631 A CN202080032631 A CN 202080032631A CN 114127274 A CN114127274 A CN 114127274A
Authority
CN
China
Prior art keywords
sequence
lys
domain
nuclease
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080032631.5A
Other languages
English (en)
Chinese (zh)
Inventor
大卫·巴拉姆
利奥尔·伊扎尔
阿塞尔·赫尔曼
利亚特·罗卡
纳达夫·马尔巴赫-巴尔
纽瑞特·梅隆
约瑟夫·乔治森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emmendo Biology
Original Assignee
Emmendo Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emmendo Biology filed Critical Emmendo Biology
Publication of CN114127274A publication Critical patent/CN114127274A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080032631.5A 2019-04-30 2020-04-30 新型omni-50 crispr核酸酶 Pending CN114127274A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962841046P 2019-04-30 2019-04-30
US62/841,046 2019-04-30
US201962897806P 2019-09-09 2019-09-09
US62/897,806 2019-09-09
US201962931630P 2019-11-06 2019-11-06
US62/931,630 2019-11-06
US202062959672P 2020-01-10 2020-01-10
US62/959,672 2020-01-10
US202062991285P 2020-03-18 2020-03-18
US62/991,285 2020-03-18
PCT/US2020/030782 WO2020223514A2 (en) 2019-04-30 2020-04-30 Novel omni-50 crispr nuclease

Publications (1)

Publication Number Publication Date
CN114127274A true CN114127274A (zh) 2022-03-01

Family

ID=73029467

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080032631.5A Pending CN114127274A (zh) 2019-04-30 2020-04-30 新型omni-50 crispr核酸酶

Country Status (10)

Country Link
US (2) US11666641B2 (https=)
EP (1) EP3963061A4 (https=)
JP (2) JP2022531347A (https=)
KR (2) KR20250060327A (https=)
CN (1) CN114127274A (https=)
AU (2) AU2020266587B2 (https=)
BR (1) BR112021021912A2 (https=)
CA (1) CA3135759A1 (https=)
IL (1) IL287693A (https=)
WO (1) WO2020223514A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
EP3823633A4 (en) 2018-06-29 2023-05-03 Editas Medicine, Inc. SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO
US11946077B2 (en) 2020-06-04 2024-04-02 Emendobio Inc. OMNI-59, 61, 67, 76, 79, 80, 81, and 82 CRISPR nucleases
WO2022098693A1 (en) * 2020-11-04 2022-05-12 Emendobio Inc. Novel omni-50 crispr nuclease-rna complexes
US20240175013A1 (en) * 2020-12-14 2024-05-30 Emendobio Inc. Biallelic knockout of trac
WO2022132765A1 (en) * 2020-12-14 2022-06-23 Emendobio Inc. Biallelic knockout of b2m
US12091688B2 (en) 2021-02-08 2024-09-17 Emendobio Inc. OMNI-103 CRISPR nuclease
KR20230142740A (ko) 2021-02-08 2023-10-11 에멘도바이오 인코포레이티드 Omni-103 crispr 뉴클레아제
IL307855A (en) * 2021-04-22 2023-12-01 Emendobio Inc OMNI CRISPR Nucleases 117, 140, 150-158, 160-165, 167-177, 180-188, 191-198, 200, 201, 203, 205-209, 211-217, 219, 220, 222, 223, 226 , 227, 229, 231-236, 238-245, 247, 250, 254, 256, 257, 260 and 262 news
IL310730A (en) * 2021-08-12 2024-04-01 Emendobio Inc Engineered high fidelity omni-50 nuclease variants
JP2024540558A (ja) * 2021-11-19 2024-10-31 エメンドバイオ・インコーポレイテッド 新規なｏｍｎｉ ｃｒｉｓｐｒヌクレアーゼ
US20250043260A1 (en) * 2021-12-01 2025-02-06 Emendobio Inc. Engineered High Activity Omni-79 Nuclease Variants
US20260021141A1 (en) * 2022-07-15 2026-01-22 Emendobio Inc. Strategies For Knock-Ins At APLP2 Safe Harbor Sites
WO2024042165A2 (en) * 2022-08-26 2024-02-29 UCB Biopharma SRL Novel rna-guided nucleases and nucleic acid targeting systems comprising such rna-guided nucleases
WO2025043140A1 (en) * 2023-08-23 2025-02-27 Emendobio Inc. Methods and compositions for modifying expression of a mutant transforming growth factor beta induced (tgfbi) allele

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015134812A1 (en) * 2014-03-05 2015-09-11 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2334794B8 (en) 2008-09-15 2017-04-19 The Children's Medical Center Corporation Modulation of bcl11a for treatment of hemoglobinopathies
EP3241902B1 (en) 2012-05-25 2018-02-28 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
WO2017024047A1 (en) 2015-08-03 2017-02-09 Emendobio Inc. Compositions and methods for increasing nuclease induced recombination rate in cells
ES2942309T3 (es) 2015-11-04 2023-05-31 Vertex Pharma Materiales y métodos para el tratamiento de hemoglobinopatías
CN105567735A (zh) * 2016-01-05 2016-05-11 华东师范大学 一种凝血因子基因突变的定点修复载体系统及方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015134812A1 (en) * 2014-03-05 2015-09-11 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
无: "type II CRISPR RNA-guided endonuclease Cas9 [Ezakiella peruensis]", 《GENBANK》 *

Also Published As

Publication number Publication date
KR20250060327A (ko) 2025-05-07
BR112021021912A2 (pt) 2022-01-18
AU2020266587A1 (en) 2021-12-16
IL287693A (en) 2021-12-01
EP3963061A2 (en) 2022-03-09
KR20220012245A (ko) 2022-02-03
US20240131121A1 (en) 2024-04-25
KR102802134B1 (ko) 2025-05-07
JP2022531347A (ja) 2022-07-06
EP3963061A4 (en) 2023-02-08
US11666641B2 (en) 2023-06-06
AU2020266587B2 (en) 2024-01-04
US20220202913A1 (en) 2022-06-30
JP2024050582A (ja) 2024-04-10
AU2024202171A1 (en) 2024-06-27
WO2020223514A2 (en) 2020-11-05
WO2020223514A3 (en) 2020-12-24
US20240226246A9 (en) 2024-07-11
CA3135759A1 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
KR102802134B1 (ko) 신규한 omni-50 crispr 뉴클레아제
AU2022200903B2 (en) Engineered Cascade components and Cascade complexes
AU2019250224B2 (en) Enhanced transgene expression and processing
CN112105389B (zh) 用于转染抵抗细胞类型的组合物
ES2819976T5 (es) Composiciones y usos médicos para la reprogramación de TCR con proteínas de fusión
KR20210068485A (ko) 노화를 역전시키고 기관 및 조직 재생을 촉진시키기 위한 세포 재프로그래밍
KR20220038362A (ko) 재조합 ad35 벡터 및 관련 유전자 요법 개선
AU2016373365B2 (en) Transposon system, kit comprising the same, and uses thereof
KR102584628B1 (ko) T-세포 수용체, t-세포 항원 및 이들의 기능성 상호작용의 식별 및 특징규명을 위한 조작된 다성분 시스템
KR20240037185A (ko) 키메라 공동자극 수용체, 케모카인 수용체, 및 세포 면역치료에서의 이의 용도
KR20220069917A (ko) 리소좀 축적 장애의 치료를 위한 벡터 조성물 및 이의 사용 방법
AU2024217163A1 (en) Transposase, transposon, transposon system, and use thereof
JP7002454B2 (ja) 遺伝子修飾アッセイ
TW202228728A (zh) 用於同時調節基因表現之組合物及方法
US20230295668A1 (en) Methods and compositions for integration of a dna construct
KR20200003160A (ko) 조혈모세포의 형질도입을 위한 개선된 렌티바이러스
CN110312803B (zh) 编辑核酸序列的组合物及方法
KR20230085912A (ko) Cd14 프로모터를 갖는 재조합 아데노 관련 바이러스 벡터 및 이의 용도
IT201900007060A1 (it) Cellule tumorali ingegnerizzate e loro usi
RU2827658C2 (ru) Сконструированные компоненты cascade и комплексы cascade
KR20120043657A (ko) 인간 혈액응고 7인자의 대량 생산 방법
RU2774631C1 (ru) Сконструированные компоненты cascade и комплексы cascade
CN116033917B (zh) 与病毒感染相关的疾病或综合征的治疗和/或预防
CN116710108A (zh) 用于同时调节诸基因表达的组合物和方法
WO2025245448A1 (en) Methods for high-throughput identification of genomic harbors for transgene expression in biological samples

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination